Preface
Preface: special issue on biliary cancer
Chinese Clinical Oncology
2016;
5
(5)
:E2
.
(31 October 2016)
Editorial
Novel therapeutic strategies targeting liver cancer stem cells
Chinese Clinical Oncology
2016;
5
(5)
:59
.
(31 October 2016)
Combination PARP and HDAC inhibition as a therapeutic strategy targeting liver cancer stem cells?
Chinese Clinical Oncology
2016;
5
(5)
:60
.
(31 October 2016)
Review Article
Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations
Chinese Clinical Oncology
2016;
5
(5)
:61
.
(31 October 2016)
Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency
Chinese Clinical Oncology
2016;
5
(5)
:62
.
(31 October 2016)
Surgical management of biliary tract cancers
Chinese Clinical Oncology
2016;
5
(5)
:63
.
(31 October 2016)
Adjuvant therapy for resected biliary tract cancer: a review
Chinese Clinical Oncology
2016;
5
(5)
:64
.
(31 October 2016)
Systemic therapy for biliary cancers
Chinese Clinical Oncology
2016;
5
(5)
:65
.
(31 October 2016)
Combined intrahepatic cholangiocarcinoma and hepatocellular carcinoma
Chinese Clinical Oncology
2016;
5
(5)
:66
.
(31 October 2016)
Gallbladder cancer: South American experience
Chinese Clinical Oncology
2016;
5
(5)
:67
.
(31 October 2016)
Percutaneous biliary interventions and complications in malignant bile duct obstruction
Chinese Clinical Oncology
2016;
5
(5)
:68
.
(31 October 2016)
Obituary
Dan Sargent, CCO Associate Editor and Mayo biostatistician and clinical trialist, dies unexpectedly at 46
Chinese Clinical Oncology
2016;
5
(5)
:69
.
(31 October 2016)
Meet the Professor
Professor William J. Gradishar: individualized treatment scheme for breast cancer
Chinese Clinical Oncology
2016;
5
(5)
:70
.
(31 October 2016)
Professor Charles E. Geyer: neoadjuvant therapy is becoming standard of care for HER2+ breast cancer
Chinese Clinical Oncology
2016;
5
(5)
:71
.
(31 October 2016)
Disclosure:
The focused issue “Biliary Cancer: Part I” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Ghassan Abou-Alfa served as the unpaid Guest Editor for the focused issue.